PuraPharm Balance Sheet Health
Financial Health criteria checks 3/6
PuraPharm has a total shareholder equity of HK$153.2M and total debt of HK$385.1M, which brings its debt-to-equity ratio to 251.3%. Its total assets and total liabilities are HK$844.0M and HK$690.7M respectively.
Key information
251.3%
Debt to equity ratio
HK$385.12m
Debt
Interest coverage ratio | n/a |
Cash | HK$42.98m |
Equity | HK$153.24m |
Total liabilities | HK$690.73m |
Total assets | HK$843.96m |
Recent financial health updates
Is PuraPharm (HKG:1498) A Risky Investment?
Sep 28PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?
Nov 02Is PuraPharm (HKG:1498) A Risky Investment?
Aug 23Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)
Feb 06Is PuraPharm (HKG:1498) A Risky Investment?
Sep 28PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?
Nov 02Is PuraPharm (HKG:1498) A Risky Investment?
Aug 23PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues
Apr 01How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?
Dec 27Financial Position Analysis
Short Term Liabilities: 1498's short term assets (HK$349.6M) do not cover its short term liabilities (HK$571.1M).
Long Term Liabilities: 1498's short term assets (HK$349.6M) exceed its long term liabilities (HK$119.6M).
Debt to Equity History and Analysis
Debt Level: 1498's net debt to equity ratio (223.3%) is considered high.
Reducing Debt: 1498's debt to equity ratio has increased from 93.3% to 251.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 1498 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 1498 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 29.2% per year.